Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps reduce your appetite by influencing two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

Lilly CEO says businesses most affected by CVS move are small employers Stock reaction to CVS decision is 'overblown,' says investor Lilly tops Wall Street view for first quarter profit, revenue ...

Zepbound (tirzepatide) is a type of drug called a glucagon-like peptide-1 (GLP-1) receptor agonist. It has the same active ingredient as the type 2 diabetes medication Mounjaro. The Food and Drug ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound Eli Lilly's stock wobbled Thursday after a looming coverage hit was ...